Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR. Brown JR, et al. Among authors: hillmen p. Haematologica. 2022 Jun 1;107(6):1335-1346. doi: 10.3324/haematol.2021.278901. Haematologica. 2022. PMID: 34587719 Free PMC article.
The evolving role of alemtuzumab in management of patients with CLL.
Faderl S, Coutré S, Byrd JC, Dearden C, Denes A, Dyer MJ, Gregory SA, Gribben JG, Hillmen P, Keating M, Rosen S, Venugopal P, Rai K. Faderl S, et al. Among authors: hillmen p. Leukemia. 2005 Dec;19(12):2147-52. doi: 10.1038/sj.leu.2403984. Leukemia. 2005. PMID: 16239912
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P. Rawstron AC, et al. Among authors: hillmen p. Leukemia. 2007 May;21(5):956-64. doi: 10.1038/sj.leu.2404584. Epub 2007 Mar 15. Leukemia. 2007. PMID: 17361231
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A; Hx-CD20-406 Study Investigators. Wierda WG, et al. Among authors: hillmen p. J Clin Oncol. 2010 Apr 1;28(10):1749-55. doi: 10.1200/JCO.2009.25.3187. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194866 Free PMC article. Clinical Trial.
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Wendtner CM, et al. Among authors: hillmen p. Leuk Lymphoma. 2012 Mar;53(3):417-23. doi: 10.3109/10428194.2011.618232. Epub 2011 Nov 15. Leuk Lymphoma. 2012. PMID: 21879809 Clinical Trial.
290 results